Guidelines for the treatment of invasive aspergillosis
Authors:
Z. Ráčil 1; J. Mayer 1; I. Kocmanová 2; J. Haber 3; N. Mallátová 4; M. Kouba 5; P. Sedláček 6; E. Faber 7; I. Herold 8; P. Múdrý 9; L. Drgoňa 10; M. Karas 11; V. Buchta 12; J. Vydra 13; M. Kolář 14; J. Trupl 15; V. Marešová 16; H. Rozsypal 16; O. Nyč 17; K. Cwiertka 18
Authors‘ workplace:
Interní hematoonkologická klinika, Fakultní nemocnice Brno a Lékařské Fakulty Masarykovy Univerzity v Brně, 2Oddělení klinické mikrobiologie, Fakultní nemocnice Brno, I. interní klinika – hematoonkologická VFN a 1. LF UK Praha, 4Laboratoř lékařské
1
Published in:
Transfuze Hematol. dnes,15, 2009, No. 1, p. 17-24.
Category:
Best Practices
Overview
An increasing incidence of invasive aspergillosis is observed in most immunocompromised patients, and especially patients with acute leukemia and after hematopoietic stem cell transplantation. In order to decrease the mortality due to this infection, the clinicians need to optimise their treatment choice. The objective of these guidelines is to summarize the current evidence for treatment of invasive aspergillosis. The recommendations have been developed by an expert panel following an evidence-based search of literature with regard to current recommendation of European Conference in Infections in Leukemia and Infectious Diseases Society of America.
Key words:
invasive aspergillosis, treatment guidelines
Sources
1. Ráčil Z, Mayer J, (eds). Invazivní aspergilóza: současné možnosti diagnostiky. Vnitř Lék 2007; 53(Suppl):
2. Herbrecht R, Fluckiger U, Gachot B, et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. European Journal of Cancer Supplements Guidelines from the First European Conference on Infections in Leukaemia: ECIL1 2007; 5: 49–59.
3. Walsh T J, Anaissie E J, Denning D W, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–360.
4. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
5. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.
6. Chen SC, Sorrell TC. Antifungal agents. Med J Aust 2007; 187: 404–409.
7. Ostrosky-Zeichner L, Marr KA, Rex JH, et al. Amphotericin B: time for a new „gold standard“. Clin Infect Dis 2003; 37: 415–425.
8. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406–1412.
9. Cordonnier C, Bresnik M, Ebrahimi R. Liposomal Amphotericin B (L-AMB) Efficacy in Invasive Filamentous Fungal Infections (IFI): Pooled Analysis. Program and abstracts of the 44th ICAAC October 30 -November 2, 2004: Abstract M-1022.
10. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289–1297.
11. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005; 40 (Suppl 6): S392–400.
12. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366.
13. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994; 97: 135–144.
14. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33: e83–90.
15. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 Suppl 1: i17–i22.
16. Viscoli C, Herbrecht R, Akan H. Caspofungin (C) as first-line therapy of invasive aspergillosis (IA) in haematological patients (pts): a study of the EORTC Infectious Diseases Group. 3th Trends in Medical Mycology 2007: Abstract O.12.
17. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337–349.
18. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36: 372–379.
19. Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18: 163–194.
20. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292–299.
21. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320–326.
22. Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448–1452.
23. Cordonnier C, Bresnik M, Ebrahimi R. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. Mycoses 2007; 50: 205–209.
24. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995; 21: 1145–1153.
25. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571.
26. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122–1131.
27. Candoni A, Mestroni R, Damiani D, et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 2005; 75: 227–233.
28. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2–12.
29. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571.
30. Kartsonis NA, Saah AJ, Joy Lipka C, et al. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. Journal of Infection 2005; 50: 196–205.
31. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025–1032.
32. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888–2897.
33. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802.
34. Raad I, Hachem R, Jiang H. Combination Salvage Therapy of Invasive Aspergillosis (IA) in Patients with Hematologic Malignancy (HM): Which Caspofungin-Containing Regimen? Program and abstracts of the 44th ICAAC 2007: M-624.
35. de Carpentier JP, Ramamurthy L, Denning DW, et al. An algorithmic approach to aspergillus sinusitis. J Laryngol Otol 1994; 108: 314–318.
36. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250–260.
37. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641–2645.
38. Subira M, Martino R, Franquet T, et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 2002; 87: 528–534.
39. Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997; 11: 1621–1630.
40. Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42: 955–963.
41. Bernard A, Caillot D, Couaillier JF, et al. Surgical management of invasive pulmonary aspergillosis in neutropenic patients. Ann Thorac Surg 1997; 64: 1441–1447.
42. Gossot D, Validire P, Vaillancourt R, et al. Full thoracoscopic approach for surgical management of invasive pulmonary aspergillosis. Ann Thorac Surg 2002; 73: 240–244.
43. Pagano L, Ricci P, Nosari A, et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell‘Adulto). Br J Haematol 1995; 89: 500–505.
44. Steinbach WJ, Benjamin DK, Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192–198.
45. Denning DW, Radford SA, Oakley KL, et al. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401–414.
46. Lass-Florl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42: 497–502.
47. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570–1572.
48. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649–663.
49. Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443–451.
50. Pasqualotto AC, Shah M, Wynn R, et al. Voriconazole plasma monitoring. Arch Dis Child 2008:
51. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–211.
52. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532–1535.
53. Dodds Ashley E, Lewis R, Lewis J, et al. Pharmacology of Systemic Antifungal Agents doi:10.1086/504492. Clinical Infectious Diseases 2006; 43: S28–S39.
54. Glasmacher A, Prentice A. Current experience with itraconazole in neutropenic patients: a concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy. Clinical Microbiology & Infection; 12: 84–90.
55. Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007; 51: 137–143.
56. Leenders A C, Daenen S, Jansen R L, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205–212.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2009 Issue 1
Most read in this issue
- Systemic mastocytosis
- Idiopathic thrombocytopenic purpura – pathogenesis, modern therapy, and an analysis of its prevalence, diagnostics and therapy in the South Moravian Region
- Guidelines for the treatment of invasive aspergillosis
- Guidelines for the treatment of invasive candidiasis